M&A Deal Summary

Heptares Therapeutics Acquires G7 Therapeutics AG

On November 30, 2016, Heptares Therapeutics acquired life science company G7 Therapeutics AG for 12M CHF

Acquisition Highlights
  • This is Heptares Therapeutics’ 1st transaction in the Life Science sector.
  • This is Heptares Therapeutics’ 0th largest (disclosed) transaction.
  • This is Heptares Therapeutics’ 1st transaction in Switzerland.

M&A Deal Summary
Date 2016-11-30
Target G7 Therapeutics AG
Sector Life Science
Buyer(s) Heptares Therapeutics
Deal Type Add-on Acquisition
Deal Value 12M CHF

Target

G7 Therapeutics AG

Schlieren, Switzerland
G7 Therapeutics AG is a developer of proprietary approaches for stabilising GPCRs (called SaBRE and CHESS), which are different and highly complementary to the StaR® platform developed by Heptares. SaBRE and CHESS are of particular use where the target GPCR is present in very low numbers on cells and the methods are particularly powerful in the numbers of stabilizing mutations that can be identified in a short time for rapidly generating high quality GPCRs.

Search 198,975 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Heptares Therapeutics

Welwyn Garden City, United Kingdom
Category Company
Founded 2007
Sector Life Science
DESCRIPTION

Heptares Therapeutics Ltd. is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Its proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal